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As the COVID-19 pandemic has evolved in the United States, state and local actions
continue to stand in stark contrast to the federal government’s. While the federal response
has been characterized as a dispute between scientific facts and political preferences, many
states are showing us the way forward. After the pandemic is over, as America continues
innovating and resolving jurisdictional and practical challenges related to health care and
medicine, including innovative therapies that straddle the line between state and federal
jurisdiction, we should consider increasing the role of state governments.
During the coronavirus pandemic, states have played important roles in the absence of
federal leadership during this pandemic, including through the use of contact tracing,
masking requirements, quarantines, and frequent public health briefings. States’
historically significant health care roles have become smaller with the expansion of the
many operating divisions of the U.S. Department of Health and Human Services. Yet,
despite the primacy of federal law in areas like drug regulation, states’ longstanding powers
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shape medicine practice through the licensing of health professionals, medical malpractice
law, and products liability regimes. States also have the advantage of being closer to
patients, although they certainly need more funding and aid in various forms.
States often complement the federal government’s actions or inactions. Several states used
budgetary allocations or even created specific agencies to fund stem cell research after the
federal funding ban announced during President George W. Bush’s administration. Some
states have also enacted legislation related to informed consent and human subjects
protection. Other states, including Texas and Florida, have been criticized for their
markets in stem cell treatments, which still exist in the absence of federal regulation. Each
of these states, and many others, can benefit from a more cooperative, shared federal-state
regulatory system.
ADVERTISEMENT
Before the pandemic, at a gathering of former FDA Chief Counsels, one former Chief
Counsel noted (at 48:27) the challenges of emerging technologies for the agency, including
the “jurisdictional and practical challenges of selling gene therapy” and how that related to
the agency’s current statutory authorizations. States and the federal government already
cooperate in many areas, including Medicaid, governmental responses to infectious
disease, and food regulation. A more cooperative framework for innovative therapies could
improve regulatory transparency, increase oversight, and facilitate the discovery of adverse
effects.
Political and social views in each state will continue to carry weight in medicine and
innovation regulation. States also face many of the same challenges as the federal
government, such as funding shortages, the possibility of regulatory capture by interested
entities, and political influences on decision-making. Yet increasing the states' role through
a more cooperative framework could improve the diversity of viewpoints in the regulatory
system in a meaningful way.
Political scientists and lawyers often quote former Supreme Court Justice Louis Brandeis’
“states as laboratories” line from New State Ice Co. v. Liebmann: “It is one of the happy
incidents of the federal system that a single courageous state may, if its citizens choose,
serve as a laboratory; and try novel social and economic experiments without risk to the
rest of the country.” In the COVID-19 context, states are certainly operating in a way that
fulfills that metaphor. Numerous lessons and changes are stemming from the pandemic,
such as improvements in access to and coverage of telehealth when the public and the
public health system shift back to focusing on non-COVID-19 concerns, the expertise and
work of state health actors may be worth leaning on in other health care situations as
well.
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